热门资讯> 正文
Exscientia将获得1500万美元的赛诺菲合作里程碑
2024-10-16 20:39
- Exscientia plc (NASDAQ:EXAI) announced the advancement of two additional discovery programmes within its collaboration with Sanofi, with Exscientia receiving an aggregate of $15M in milestone payments.
- Both lead compounds have met the product profile requirements, set by both Exscientia and Sanofi, to enable a transition to the lead optimisation phase within the collaboration.
- The payment is expected to be received by Exscientia in the fourth quarter of 2024 and reflected as cash inflows from collaborations and recognised as revenue over the duration of the collaboration.
- For these two programs, Exscientia may receive over $300M in pre-commercial and over $300M in commercial milestone payments, plus tiered royalties on sales ranging from high single digits to mid-teens, contingent on achieving specific research, development, regulatory, and commercial milestones.
- Source: Press Release
More on Exscientia
- Recursion's Acquisition Of Exscientia Makes Sense On Some Levels, Not Others
- Recursion, Exscientia seek support for merger ahead of special meeting
- Nvidia-backed Recursion to acquire Exscientia in all-stock deal
- Seeking Alpha’s Quant Rating on Exscientia
- Historical earnings data for Exscientia
推荐文章
风险及免责提示：以上内容仅代表作者的个人立场和观点，不代表华盛的任何立场，华盛亦无法证实上述内容的真实性、准确性和原创性。投资者在做出任何投资决定前，应结合自身情况，考虑投资产品的风险。必要时，请咨询专业投资顾问的意见。华盛不提供任何投资建议，对此亦不做任何承诺和保证。
